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lthough NH
 
2
 
-terminal mutant huntingtin (htt) frag-
ments cause neurological disorders in Huntington’s
disease (HD), it is unclear how toxic htt fragments
are generated and contribute to the disease process. Here,
we report that complex NH
 
2
 
-terminal mutant htt fragments
smaller than the ﬁrst 508 amino acids were generated in
htt-transfected cells and HD knockin mouse brains. These
fragments constituted neuronal nuclear inclusions and
A
 
appeared before neurological symptoms. The accumulation
and aggregation of these htt fragments were associated with
an age-dependent decrease in proteasome activity and were
promoted by inhibition of proteasome activity. These results
suggest that decreased proteasome activity contributes to
late onset htt toxicity and that restoring the ability to remove
 
NH
 
2
 
-terminal fragments will provide a more effective therapy
for HD than inhibiting their production.
 
Introduction
 
Huntington’s disease (HD) is characterized by progressive
and late onset neurodegeneration, which is caused by a
 
polyglutamine (polyQ) expansion in the NH
 
2
 
-terminal region
of huntingtin (htt), a 350-kD protein of unknown function.
 
A number of studies have shown that NH
 
2
 
-terminal fragments
of mutant htt are cytotoxic. For example, transfection of
NH
 
2
 
-terminal mutant htt causes cells to die (Cooper et al.,
1998; Hackam et al., 1998; Li et al., 1999). HD transgenic
 
mice expressing small NH
 
2
 
-terminal htt (
 
 
 
171 aa) with
an expanded polyQ tract show progressive neurological
phenotypes and early death (Davies et al., 1997; Schilling
et al., 1999).
The toxicity of NH
 
2
 
-terminal mutant htt is also indicated
by its abnormal protein conformation including misfolding,
aggregation, and the formation of inclusions. Like other
types of protein inclusions, polyQ-containing inclusions are
associated with the ubiquitin–proteasome complex, a large
multicatalytic–protease complex that is able to remove
misfolded proteins to maintain a healthy cellular environment
(Lee and Goldberg, 1998). Inhibition of proteasome activity
increases polyQ protein aggregation and toxicity in cultured
cells (Orr, 2001). The abnormal protein conformation of
NH
 
2
 
-terminal htt may be responsible for its aberrant nuclear
accumulation and interactions with other proteins, leading
to altered gene expression and neuropathology in HD. In an
attempt to develop a therapeutic strategy to inhibit the
generation of toxic htt fragments, experiments to identify
NH
 
2
 
-terminal mutant htt fragments have uncovered caspase
and calpain cleavage products (Kim et al., 2001; Gafni and
Ellerby, 2002; Goffredo et al., 2002; Wellington et al., 2002).
Other NH
 
2
 
-terminal fragments of mutant htt generated by
unknown proteases were also identified in cultured cells
(Lunkes et al., 2002; Sun et al., 2002). However, how these
fragments are associated with neuropathology and whether
they form nuclear inclusions in HD brain cells remain unclear.
The difficulty in defining toxic NH
 
2
 
-terminal htt fragments
in the brain stems from the inherent protein misfolding
conferred by polyQ expansion. The polyQ-mediated confor-
mational change results in unpredictable immunoreactivity
and altered protein mobility on SDS gels, thereby making it
 
difficult to identify the true size of NH
 
2
 
-terminal htt
fragments in the brain. In addition, postmortem HD brains
are often poorly preserved, so their unknown integrity imposes
additional difficulty in analyzing htt proteins.
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To circumvent these difficulties, we used several criteria to
identify NH
 
2
 
-terminal htt fragments that are genuinely
toxic and likely to be associated with HD. First, toxic NH
 
2
 
-
terminal htt fragments must carry an expanded polyQ re-
peat and should be found specifically in the HD brain. Sec-
ond, toxic NH
 
2
 
-terminal htt fragments should be able to
accumulate in the nucleus and form inclusions. Third, the
accumulation of toxic NH
 
2
 
-terminal htt fragments should
be associated with disease progression. We used HD repeat
knockin mouse brains, which allow observation of the initial
formation of NH
 
2
 
-terminal htt and its aggregates. Here, we
provide evidence that the complex NH
 
2
 
-terminal mutant
htt fragments accumulate in the nucleus and form aggre-
gates in association with the age-dependent decrease of pro-
teasome activity. These results suggest that removing these
toxic NH
 
2
 
-terminal htt fragments may be an effective ther-
apy to prevent htt toxicity.
 
Results
 
Immunoreactivity of anti-htt antibodies
 
Using human embryonic kidney 293 (HEK293) cells
transfected with the first 508 aa of htt containing 23
(N508-23Q)– or 120 (N508-120Q)–glutamine repeats,
we compared the immunoreactivity of some of widely used
antibodies. These antibodies included EM48, a rabbit anti-
body against the first 256 aa of htt with a deletion of the
polyQ domain (Gutekunst et al., 1999); 1C2, a mouse
mAb against expanded polyQ tracts (Lunkes et al., 2002);
and 2166, a mouse mAb against htt amino acids 181–810
(Dyer and McMurray, 2001). We also generated a rabbit
antibody (EM121) that reacts with human htt amino acids
342–456 (Fig. 1 A). All these antibodies reacted with the
intact form (
 
 
 
110 kD) of N508-120Q (Fig. 1 B). When
cells were transfected for 72 h, 1C2, EM48, and 2166 rec-
ognized many small bands ranging from 40 to 90 kD in
N508-120Q cells. Among them, 1C2 immunoreactive
bands certainly represent NH
 
2
 
-terminal mutant htt frag-
ments containing an expanded polyQ domain, as 1C2
failed to detect any bands of transfected htt containing a
normal repeat (N508-23Q). The bands corresponding to
1C2 immunoreactive products were also seen on the
EM48-probed blot (Fig. 1 B, arrowhead). Antibody 2166
labeled the same small bands that were present in both
N508-120Q and N508-23Q samples, suggesting that
these bands do not contain an expanded polyQ domain.
EM121 did not label bands 
 
 
 
80 kD in N508-120Q sam-
ples. Thus, small sized bands (
 
 
 
80 kD) labeled by both
EM48 and 1C2 are likely to be NH
 
2
 
-terminal mutant htt
fragments smaller than the first 342 aa of htt. However,
1C2 did not label aggregated htt in the stacking gel. In
contrast, EM48 intensely reacted with the aggregated htt
on Western blots.
We also compared the immunoreactivity of these antibod-
ies by immunocytochemistry. Overexpressed N508-120Q
formed a few cytoplasmic aggregates in HEK293 cells,
which were labeled by 2166, EM121, and EM48 (Fig. 1 C).
This result suggests that polyQ aggregation did not mask
the epitopes for 2166 and EM121. Immunostaining of
HdhCAG150 mouse brains, however, only showed EM48-
immunoreactive aggregates in the nucleus (Fig. 1 D). This
result suggests that the brain aggregates do not contain
epitopes that are recognizable by 2166 and EM121, or are
formed by htt fragments smaller than the first 342 aa. 1C2
failed to detect htt aggregates in transfected cells (not de-
picted) and in HD brain (Fig. 1 D). The comparison of
these antibodies indicates that 1C2 is particularly useful to
detect the soluble form of mutant htt, whereas EM48 is the
most sensitive to aggregated htt.
 
Composition of htt aggregates in brains of HD patients
 
Next, we examined htt aggregates in the caudate brain re-
gion from an HD patient with grade 3 neuropathology.
Double immunofluorescence staining only showed EM48-
labeled htt aggregates, which were negative to 1C2, 2166,
and EM121 labeling (Fig. 2 A). This result also suggests that
htt aggregates in the human brain primarily consist of small
NH
 
2
 
-terminal htt fragments.
Figure 1. Immunoreactivity of anti-htt antibodies. 
(A) The regions of NH2-terminal htt that were used 
for generating antibodies. 1C2 reacts with an 
expanded polyQ tract (triangle). (B) Western blot 
analysis of transfected htt with antibodies 1C2, 
EM48, 2166, and EM121. NH2-terminal htt 
(1–508 aa) containing a 23 (23Q)– or 120 (120Q)–
glutamine repeat was expressed in HEK293 cells 
that had been transfected for 72 h. NH2-terminal 
htt fragments containing the expanded 120Q 
domain are marked with asterisks. Arrow indicates 
aggregated htt. Control, nontransfected cells. 
(C) Immunofluorescence double labeling of 
N508-120Q–transfected HEK293 cells with 2166 
and EM48 (top) or EM121 with mouse antibody 
mEM48 (bottom). Arrows indicate cytoplasmic 
htt aggregates. (D) Immunostaining of the striatum 
of a homozygous HdhCAG150 mouse at 9 mo old 
with 1C2, 2166, EM121, and EM48. Only EM48 
immunoreactive aggregates were seen. Bars: 
(C and D) 5  m.T
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Several studies have shown that the homogenates of post-
mortem brains of HD patients display a smear of 1C2 im-
munoreactive products on Western blots (Kim et al., 2001;
Lunkes et al., 2002; Wellington et al., 2002). However, the
composition of nuclear htt inclusions in the brain is unclear.
Therefore, we isolated htt inclusions from the brains of HD
patients and dissolved them with formic acid. A very intense
1C2 smear was seen in the dissolved aggregates (Fig. 2 B).
Although EM48 and antiubiquitin antibodies labeled aggre-
gated proteins, these antibodies reacted weakly with dis-
solved htt (Fig. 2 C), suggesting that dissolved mutant htt
possesses a different conformation that is more recognizable
by 1C2. EM121 did not recognize htt aggregates or their
dissolved products (Fig. 2 C).
 
Multiple NH
 
2
 
-terminal htt fragments in HD mouse brain
 
The smear of 1C2 immunoreactive products in the HD
brain sample may result from htt oligomerization or con-
jugation with other molecules over time in the human
brain, precluding any analysis of the size of htt fragments.
Therefore, we examined HD repeat knockin mice
(HdhCAG150), which express a 150–glutamine repeat in
endogenous mouse htt (Lin et al., 2001). These mice show
progressive neurological symptoms beginning at the age of
4–5 mo (Lin et al., 2001). Using EM121, we found that the
mutant and normal alleles were expressed at equivalent levels
from 3 to 18 mo (Fig. 3 A). Products immunoreactive to
1C2 were seen only in the HD mouse brain, again support-
Figure 2. Aggregated NH2-terminal htt in the cortex of HD patient 
brains. (A) Double immunofluorescence labeling of a striatal section 
of an HD patient brain with mouse EM48 (mEM48) and EM121 or 
rabbit EM48 and 2166. Only EM48 reacted with htt aggregates in 
the brain. Arrows indicate htt aggregates. Bar, 5  m. (B) The nuclear 
fractions of the striatum from control (C), HD, and Alzheimer’s disease 
(AD) were dissolved with formic acid (FA) and resolved by SDS-PAGE. 
Products immunoreactive to 1C2 were not seen without FA treatment 
( FA) but appeared as a smear in the HD sample after FA treatment 
( FA). (C) FA treatment reduced the amount of EM48 or ubiquitin-
labeled aggregates (arrow). EM48 and antiubiquitin reacted weakly 
with dissolved htt aggregates. EM121 did not label aggregated or 
dissolved htt. The blots were also probed with antibody against 
tubulin (Tub).
Figure 3. Complex NH2-terminal htt fragments formed in 
HdhCAG150 mice. (A) Homogenates of brain cortex from wild-type 
and heterozygous HdhCAG150 mice at 3, 6, 10, and 18 mo old 
were analyzed by Western blotting with EM121 or 1C2. Note that 
no 1C2 immunoreactive products were seen in the wild-type (WT) 
mouse brain. In vitro–synthesized N508-120Q was included to 
estimate the size of htt in the brain. (B) Extracts of various brain 
regions (Str, striatum; Cereb, cerebellum; and Ctx, cortex) from 
heterozygous HdhCAG150 mice at different ages (2, 6, and 12 wk, 
or 16 mo) were analyzed by Western blotting with 1C2. Arrow 
indicates full-length mutant htt. (C) Cytoplasmic and nuclear fractions 
of HD mice at the age of 3, 5, or 12 wk were analyzed by 1C2 
Western blotting. Arrow indicates full-length htt. (D) Nuclear 
aggregates isolated from HD mouse cortex were treated with FA 
and analyzed by Western blots with 1C2 antibody. Note that distinct 
1C2 immunoreactive products were present in dissolved aggregates 
from 3-mo-old HD mice and became a smear over time. The brackets 
in B–D show multiple NH2-terminal htt fragments that are smaller 
than N508-120Q. The blots were also probed with antibodies against 
tubulin (Tub) or the neuron-specific nuclear protein NeuN.T
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ing the idea that they are NH
 
2
 
-terminal mutant htt. Strik-
ingly, small 1C2 immunoreactive bands became prominent
with increasing age, reflecting the accumulation of NH
 
2
 
-ter-
minal mutant htt in old animals (Fig. 3 A). In vitro–synthe-
sized N508-120Q was then included to estimate the size of
the NH
 
2
 
-terminal htt fragments in the HD brain. Because
mutant htt in HD mice contains a longer repeat (150Q),
1C2-labeled bands that were smaller than N508-120Q (110
kD) certainly represent htt fragments shorter than the first
508 aa of htt. To further examine whether these fragments
were generated in young HD mice (
 
 
 
3 mo), we isolated
various brain regions from 2 wk–16-mo-old HD mice and
found that multiple 1C2 immunoreactive bands were also
present in these regions. Noticeably, the amount of these
1C2 bands was less in the cerebellum than in the striatum
and cortex, perhaps because of the low level of full-length
mutant htt in this brain region. A more strikingly finding is
that these NH
 
2
 
-terminal htt fragments were generated even
at the age of 2 wk (Fig. 3 B). This clearly indicates that the
generation of multiple NH
 
2
 
-terminal htt fragments precedes
any detectable neurological symptoms, as HdhCAG150
mice usually exhibit neurological phenotypes at the age of
5–6 mo (Lin et al., 2001).
It would be interesting to know whether these NH
 
2
 
-ter-
minal htt fragments are also present in the nucleus. Next, we
compared 1C2 immunoreactive products in cytosolic and
nuclear fractions of the cortex of HD mice at the age of
3–12 wk. With a longer exposure of Western blots, multiple
htt fragments were obviously seen in these samples (Fig. 3
C). Most htt fragments seen in the nuclear fraction were
 
 
 
110 kD (Fig. 3 C, bracket), suggesting that these smaller
fragments were prone to nuclear accumulation.
Next, we isolated nuclear htt aggregates from HD mouse
brains and dissolved them using formic acid. Several distinct
bands were observed in the dissolved htt aggregates. How-
ever, these bands were distinguishable only in young mice at
the age of 3 mo and, as the age increased (from 6 to 18 mo),
they became a smear resembling the smear seen on Western
blots of the brain of HD patients. In addition, the bands in
older mouse brains appeared to be larger, owing to the oligo-
merization or conjugation of intranuclear htt in aged neu-
rons (Fig. 3 D). Thus, nuclear htt inclusions may be initially
formed by multiple NH
 
2
 
-terminal htt fragments (smaller
than the first 508 aa), which then become oligomerized or
aggregated in an age-dependent manner.
 
Cleavage of small NH
 
2
 
-terminal htt fragments
 
Complex NH
 
2
 
-terminal htt fragments seen in the HD
mouse brain reflect multiple cleavage products of htt. To
examine whether mouse brain extracts could also cleave
NH
 
2
 
-terminal htt to small fragments in vitro, we used an
in vitro cleavage method as described previously (Kim et
al., 2001; Wellington et al., 2002) to examine how the in
vitro–synthesized N508-120Q is digested by mouse brain
extracts. The experiment included mouse brain extracts of
the cortex, cerebellum, striatum, hippocampus, and brain
stem. Multiple fragments were observed after the in vitro
digestion by these tissue extracts. However, no tissue-spe-
cific band was observed under these conditions (Fig. 4 A).
Inclusion of N508-23Q verified that these htt products
did contain a polyQ domain (Fig. 4 B), as evidenced by
the repeat length–dependent migration of these bands
on the SDS gel. When incubated with a mix of protease
inhibitors, some of these NH
 
2
 
-terminal htt fragments
were significantly inhibited. A caspase inhibitor (ZVAD),
which inhibits a variety of caspases, did not affect these htt
fragments, perhaps because caspase cleavage occurs at posi-
tions at and beyond amino acid 513 (Kim et al., 2001;
Wellington et al., 2002).
 
Multiple NH
 
2
 
-terminal htt fragments in stably 
transfected cells expressing full-length mutant htt
 
To confirm that complex NH
 
2
 
-terminal htt fragments are
generated from full-length mutant htt, we established stably
transfected HEK293 cells (23Q-F or 120Q-F) that express
full-length htt containing a 23Q or 120Q repeat. Immuno-
staining of 120Q-F cells showed that these cells formed htt
aggregates only when they had been cultured for 3–4 d (Fig.
5 A). Because only NH
 
2
 
-terminal mutant htt forms aggre-
gates, Western blots were performed to examine the genera-
tion of NH
 
2
 
-terminal htt in these cells. Compared with
23Q-F cells, 120Q-F cells clearly showed more NH
 
2
 
-termi-
nal mutant htt fragments that were intensely labeled by
EM48 (Fig. 5 B). Their amount increased after culturing for
3–4 d. Also, the size of these fragments ranged from 55 to
98 kD, consistent with the idea that they are smaller than
the first 500 aa of htt.
Figure 4. Lack of caspase cleavage of NH2-terminal htt. (A) In vitro–
synthesized htt (N508-120Q) was digested by 100  g protein extracts 
of various mouse brain regions (Ctx, cortex; Cereb, cerebellum; Stria, 
striatum; Hippo, hippocampus; B.S, brain stem; and 293, HEK293 
cell lysates). Degraded htt products were revealed by mEM48 
Western blotting. (B) Fragments of N508-23Q and N508-120Q that 
were cleaved by mouse cortex extracts showed repeat-dependent 
mobility on a Western blot. Some of these fragments were inhibited 
by a mix of protease inhibitors (P.I.) but not by 50  M of caspase 
inhibitor (ZVAD). Cortex extract alone (Ctx only) served as a control 
to verify that the mEM48-labeled products were specifically derived 
from the in vitro–synthesized htt. Probing the blots with antitubulin 
(Tub) showed that the equal amounts of brain lysates were used.T
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The viability of 23Q-F and 120Q-F cells did not differ
significantly under normal culture conditions (unpublished
data), perhaps because htt toxicity is dependent on the accu-
mulation of cleaved NH
 
2
 
-terminal htt fragments. It is possi-
ble that mutant htt in these cells mediates early pathological
events or confers cellular vulnerability to certain insults.
Thus, we treated these cells with the mitochondrial toxin
3-nitropropionic acid (3-NP), which has been used to estab-
lish HD animal models (Beal et al., 1993). Using modified
3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bro-
mide (MTS) assay that detects early apoptotic events, we
found that 3-NP significantly reduced the viability of cells
carrying 120Q-F (36.8% 
 
  
 
6.4) as compared with 23Q-F
cells (78.3% 
 
  
 
8.2) and nontransfected cells (82.1% 
 
 
 
12.3). Hydrogen peroxide, another oxidative stress insult,
also caused a significant decrease in the viability of 120Q-F
cells (33.3% 
 
  
 
7.2) relative to 23Q-F (68.1% 
 
  
 
8.3) and
control cells (88.5%
 
  
 
 9.8; Fig. 5 C, 
 
n 
 
  
 
4). The MTS as-
say has been widely used to measure cell viability, as it is able
to detect the function of dehydrogenases and thus, measures
mitochondrial dysfunction during early stages of cell death.
However, this dysfunction may not always reflect apoptotic
events. Although no significant morphological changes were
seen in 120Q-F cells under the normal culturing conditions,
we wanted to know whether 3-NP treatment could lead
these cells to have nuclear fragmentation that reflects cell
death. By examining the nuclear morphology of cultured
cells, we found that more 120Q-F cells (15.25% 
 
  
 
1.75
[mean 
 
  
 
SEM]) had obvious abnormal or fragmented
nuclei than did 23Q-F cells (7.25 
 
 
 
 1.25) and nontrans-
fected cells (4.5% 
 
  
 
0.64; Fig. 5 D). Analysis of variance
(ANOVA) and posthoc Scheffe’s test showed significant dif-
ferences between 120Q-F cells and nontransfected cells
(P 
 
  
 
0.0011; F 
 
  
 
33.21; and 
 
n 
 
  
 
4) or 23Q-F cells (P 
 
 
 
0.0098; F 
 
  
 
13.8; and 
 
n 
 
  
 
4). Considering the increased
generation of htt fragments in these 120Q-F cells, these re-
sults suggest the association of NH
 
2
 
-terminal htt fragments
with increased sensitivity to oxidative toxins. The increased
levels of NH
 
2
 
-terminal mutant htt could result from the de-
creased ability to remove these fragments. Because protea-
some activity in cultured cells often decreases after pro-
longed culturing (Starke-Reed and Oliver, 1989; Dardevet
et al., 1995; Petropoulos et al., 2000; Bulteau et al., 2000),
we examined proteasome activity of cultured cells and found
a lower activity in old cultured cells, including wild-type,
23Q-F, and 120Q-F cells (Fig. 5 E). This decrease appar-
ently paralleled the increased amount of NH
 
2
 
-terminal htt
in 120Q-F cells, suggesting that decreased proteasome activ-
ity promotes the accumulation of NH
 
2
 
-terminal mutant htt.
 
Age-dependent decrease in brain proteasome activity
 
The inverse correlation between decreased proteasome activ-
ity and increased accumulation of NH
 
2
 
-terminal htt in
120Q-F cells led us to examine whether proteasome activity
also decreases in aged HD neurons, which contain more
NH
 
2
 
-terminal htt fragments. Because small NH
 
2
 
-terminal
htt accumulates in the nucleus, we first examined the nu-
clear distribution of htt in HdhCAG150 mouse brains. In
the striatum, nuclear htt staining was evident at 3 mo old.
As the mice aged, intranuclear htt staining became more in-
tense and formed nuclear aggregates (Fig. 6 A). These results
are consistent with Western blot results showing that more
NH
 
2
 
-terminal htt fragments accumulated in older HD
mouse brains (Fig. 3 A). We also observed many htt aggre-
gates in the cortex in HdhCAG150 mice (unpublished
data), perhaps because a large repeat (150Q) reduces the tis-
Figure 5. Toxic NH2-terminal htt 
fragments in full-length mutant htt-
transfected cells. (A) HEK293 cells stably 
transfected with full-length htt containing 
a 120 (120Q-F)–glutamine repeat 
displayed EM48-labeled aggregates in 
3–4-d-old cultured cells. (B) Western 
blot analysis of 120Q-F and 23Q-F cells 
showing that EM48 immunoreactive 
fragments smaller than the first 500 aa 
of htt (bracket) were accumulated in 
cultured cells at days 3–4. Arrow indicates 
full-length htt. (C) A greater decrease in 
the viability of 120Q-F cells was observed 
after treatment with 5 mM of oxidative 
insults 3-NP and 200  M of hydrogen 
peroxide for overnight. Control is cells 
without drug treatment. The data (mean   
SD) were expressed as percentage of 
control. ANOVA and posthoc Scheffe’s 
test confirmed a statistical difference 
between 120Q-F and 23Q-F cells or 
nontransfected cells.**, indicates 
P   0.0003; F   30.71; and n   4. 
(D) Representative images of 23Q-F or 
120Q-F cells treated with 10 mM 3-NP 
overnight. Cells were stained with anti-htt (mEM48) antibody and the nuclear dye Hoechst. Arrows indicate fragmented nuclei. (E) Proteasome 
activity of cultured cells was decreased after prolonged culture (3–4 d). The data are expressed as mean   SD (n   3). The proteasome activity 
of WT cells at day 1 is presented as 100%. Error bars represent mean   SD.T
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sue-specific distribution of polyQ protein, as reported in
SCA1 mouse model (Watase et al., 2002). However, in the
same animal, more intranuclear htt aggregates were often
observed in the striatum than in the cortex.
Next, we measured the hydrolysis of Suc-Leu-Leu-Val-
Tyr-4-methyl-coumaryl-7-amide (Suc-LLVY-MCA) by chy-
motrypsin-like proteasomes in brain homogenates from
wild-type and HD mice at 1–24-mo old (Fig. 6 B). Three
brain regions of these mice were examined: the cerebral cor-
tex, the striatum, and the cerebellum. We did not see any
significant difference in this proteasome activity between
normal and HD mouse brains at various ages (unpublished
data). However, all the brain tissues examined showed de-
creasing proteasome activity as the mice aged. The striatum
showed the greatest reduction in activity from 1 to 4 mo. Af-
ter 8 mo, the activity decreased steadily and slowly. Al-
though chymotrypsin-like activity is lower in the nucleus
than in the cytosolic lysates, nuclear proteasome activity also
decreased in an age-dependent fashion (Fig. 6 C). The activ-
ity of postglutamyl peptidase, which uses Z-LLLE- Nap as
a substrate and is also present in 20S proteasome (Piccinini
et al., 2000), also decreased in the striatal cells (unpublished
data). The significant decrease of proteasome activity from 1
to 3 mo is fairly consistent with the increased nuclear stain-
ing of htt and the increased accumulation of NH2-terminal
htt fragments in HdhCAG150 mice.
Accumulation of NH2-terminal htt by inhibiting 
proteasome activity
If decreased proteasome activity causes the increased amount
of NH2-terminal htt, inhibiting proteasomes should also
promote the accumulation of NH2-terminal htt fragments.
We performed three sets of experiments to test this hy-
pothesis. First, HEK293 cells that had been transfected
with N508-23Q or N508-120Q were treated with N-acetyl-
leucinal-leucinal-norleucinal (ALLN) and lactacystin, which
are used to inhibit proteasomes in a variety of systems
(Johnston et al., 1998; Lee and Goldberg, 1998). Transfec-
tion of cells for 24 h gave rise to a prominent band of intact
transfected htt, but proteasome inhibition resulted in a sig-
nificant increase in small NH2-terminal htt fragments (Fig.
7 A). More NH2-terminal htt products were present in
N508-23Q cells than in N508-120Q cells after inhibiting
proteasomes, perhaps because NH2-terminal htt fragments
containing 120Q were unstable and quickly became ag-
gregates, especially when proteasomes are inhibited. Indeed,
aggregated htt that remained in the stacking gel was labeled
by EM48.
Our second experiment was to examine whether decreased
proteasome activity in brain tissue could promote the accu-
mulation of NH2-terminal htt. To do so, we incubated the
in vitro–synthesized NH2-terminal htt (N508-120Q) with
striatal extracts from mice at 1 or 3 mo old (Fig. 7 B). In the
absence of protease inhibitors, the in vitro–synthesized htt
had several degraded fragments, allowing us to examine their
digestion by tissue proteasomes. It appeared that brain ex-
tracts from 1-mo-old mice removed more fragments than
did the extracts from 3-mo-old mice, consistent with the
higher proteasome activity in the younger animals. Inhibit-
ing proteasomes by lactacystin restored these NH2-terminal
htt fragments. Furthermore, htt products were seen that
were larger than the intact form of N508-120Q, especially
when htt was treated with lactacystin and incubated with the
older brain extracts. This result suggests that inhibiting pro-
teasome activity also promotes the oligomerization or conju-
gation of NH2-terminal mutant htt.
In our third experiment, we examined whether protea-
some inhibition could increase the accumulation of endoge-
nous NH2-terminal mutant htt fragments in HD brain. Af-
ter treating the nuclear extracts of HD mouse striatum with
Figure 6. Age-dependent decrease of proteasome activity and increase in nuclear accumulation of mutant htt. (A) The striatal region from 
homozygous HdhCAG150 mice at 1, 3, 5, and 9 mo old was stained with EM48. Htt aggregates increased with the age of the brain. Bar, 10  m. 
(B) Chymotrypsin-like proteolysis was assayed in homogenates from various brain regions of 1–24-mo-old mice. Error bars represent mean   SD. 
(C) The cytoplasmic and nuclear fractions of the cortical and striatal tissues were examined for chymotrypsin-like activity at various ages (1, 3, 
and 8 mo). Proteasome activity is expressed as nanomol/minute/milligram protein (mean   SD; and n   3–5 mice).T
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lactacystin, we also observed a significant increase in multi-
ple 1C2 immunoreactive products and, more importantly,
an increase in the oligomerized or aggregated htt of high
molecular weight (Fig. 7 C). These oligomerized or aggre-
gated htt proteins were not labeled by antiubiquitin anti-
body (unpublished data). It is likely that ubiquitination of
aggregated htt requires time such that those htt aggregates
that form rapidly in vitro or in transfected cells are often not
ubiquitin immunoreactive.
Discussion
Given that NH2-terminal htt fragments with an expanded
polyQ domain are toxic to neurons, reducing their produc-
tion or removing them would be beneficial for treating HD.
However, effective inhibition of mutant htt degradation
largely depends on the identification of htt fragments and
their cleavage sites. Previous studies have focused on how
mutant htt fragments are generated (DiFiglia et al., 1997;
Kim et al., 2001; Mende-Mueller et al., 2001; Gafni and
Ellerby, 2002; Lunkes et al., 2002; Wellington et al., 2002).
As a result, various htt fragments were identified. However,
the nature of toxic NH2-terminal htt fragments in the HD
brain is still poorly understood. This paper demonstrates
that complex NH2-terminal htt fragments are naturally gen-
erated in the HD brain before neurological symptoms and
suggests that an age-dependent decrease in clearance of these
fragments is important for the development of the disease.
A number of NH2-terminal htt fragments of varying sizes
have been found in the brains of HD patients (DiFiglia et
al., 1997; Kim et al., 2001; Mende-Mueller et al., 2001).
The variable integrity of postmortem brain tissues examined
and the varied immunoreactivity of antibodies used may
cause inconsistent results regarding the size of NH2-terminal
htt fragments. Another obstacle to analyzing NH2-terminal
htt fragments stems from unpredictable protein conforma-
tional changes caused by polyQ expansion. NH2-terminal
htt fragments, once generated from full-length htt, may be
unstable or possess varied immunoreactive properties. For
example, although EM48 reacts well with NH2-terminal htt
fragments in transfected cells, it is poor in recognizing brain
NH2-terminal htt fragments on blots. This may explain why
very few NH2-terminal htt fragments have been found in
HD mouse brains with EM48 Western blots (Li et al., 2000;
Wheeler et al., 2000). NH2-terminal mutant htt might be ei-
ther rapidly degraded by the proteasome or become mis-
folded and aggregated to form visible inclusions. Indeed, re-
ducing polyQ oligomerization was found to promote the
degradation of polyQ proteins and to inhibit their toxicity
(Sanchez et al., 2003). It remains to be investigated how sol-
uble mutant htt forms aggregates. However, it is possible
that protein conformational changes caused by polyQ ex-
pansion create an epitope that is more recognizable by 1C2
on Western blots, and such an epitope is lost or masked dur-
ing polyQ aggregation such that 1C2 is unable to react with
aggregated htt. This explains why 1C2 fails to detect distinct
NH2-terminal htt fragments in aged patient brains (Dyer
and McMurray, 2001) but often recognizes a smear after dis-
solving aggregated htt (Lunkes et al., 2002; Wellington et
al., 2002). Thus, HD mice at young ages would provide a
better system to uncover NH2-terminal htt fragments that
have not been aggregated. Also, the HD mice we examined
express a 150–glutamine repeat. This large repeat signifi-
cantly increased 1C2 immunoreactivity, allowing us to reveal
more NH2-terminal htt fragments than reported previously.
Figure 7. Effect of inhibiting proteasome activity on the 
accumulation of NH2-terminal htt fragments. (A) HEK293 cells 
transfected with N508-23Q or N508-120Q for 24 h were treated 
with vehicle (DMSO), 20  g/ml ALLN, 20  M lactacystin (Lact), or 
50  M ZVAD overnight. EM48 Western blots revealed multiple htt 
fragments, htt of high molecular mass (bracket), and aggregated htt 
(arrow) after ALLN and Lact treatment. (B) In vitro–synthesized 
N508-120Q was incubated with 100  g protein of mouse striatal 
extracts in the absence ( Lac) or the presence ( Lac) of 20  M 
lactacystin for 1 h. Note that 1-mo-old (1m) striatal extracts removed 
more 1C2 immunoreactive fragments than did the extracts from 
3-mo-old (3m) mice. Inhibiting the proteasome by lactacystin 
increased the amount of NH2-terminal htt products and their oligo-
merization or conjugation (bracket). Blots were also probed with 
antitubulin (bottom, Tub). (C) Striatal extracts from HdhCAG150 ( / ) 
mice at 4 wk old were treated with lactacystin ( Lac, 20  M) for 1 h, 
resulting in more 1C2 immunoreactive fragments and htt of high 
molecular mass (bracket). Relative signal ratios of the intact form of 
N508 htt to tubulin (N508/Tub) are shown.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
C
e
l
l
 
B
i
o
l
o
g
y
116 The Journal of Cell Biology | Volume 163, Number 1, 2003
Proteins identified by 1C2 in this paper certainly repre-
sent toxic NH2-terminal htt fragments in the brain. First,
their formation precedes disease symptoms, and their in-
creased accumulation is well correlated with disease progres-
sion. Second, unlike full-length mutant htt, small 1C2
immunoreactive products accumulate in the nucleus, in-
dicating that they are translocated into the nucleus and
may affect gene expression. Third, oligomerization of polyQ
proteins is toxic to cells (Sanchez et al., 2003). Small 1C2
immunoreactive products are oligomerized and aggregated.
In support of this, dissolving nuclear inclusions revealed a
similar complex of 1C2 immunoreactive products. Fourth,
the generation of similar NH2-terminal htt fragments in
transfected cells is closely associated with the increased vul-
nerability to oxidative toxins. Furthermore, the cytotoxicity
of small NH2-terminal htt fragments has been convincingly
demonstrated in HD transgenic mice (Davies et al., 1997;
Schilling et al., 1999).
Some of the NH2-terminal htt fragments observed in our
work might be generated from the identified cleavage sites
by caspase-3, calpain, and an unknown aspartic endopepti-
dase (Gafni and Ellerby, 2002; Kim et al., 2001; Lunkes et
al., 2002; Wellington et al., 2002). However, the repeat-
dependent mobility on the blots makes it difficult to com-
pare the size of NH2-terminal htt fragments we observed
with that of different htt or different polyQ repeats in other
studies. Despite this, it is evident that multiple NH2-termi-
nal htt fragments are present in very young animals, suggest-
ing that various proteases are actively producing these frag-
ments throughout the animal’s lifetime.
The concentration of specific NH2-terminal htt fragments
is determined by their rates of generation and degradation.
Examination of several brain regions did not reveal any tis-
sue-specific 1C2 immunoreactive fragment. We cannot rule
out the possibility that tissue-specific htt products are unsta-
ble or rapidly subjected to further modification or digestion.
This paper shows that further degradation of multiple NH2-
terminal htt products plays a critical role in their turnover.
Although chaperones prevent misfolding of proteins, the
ubiquitin–proteasome systems degrade small polyQ peptides
or misfolded proteins (Orr, 2001). The proteasome is a large
multicatalytic–protease complex, which exists as 20S ( 700
kD) and 26S ( 2,000 kD) particles (Coux et al., 1996).
The 20S particle, the catalytic core of the proteasome, is
composed of 14 discrete but related subunits. A recent paper
using oligonucleotide assays shows that the ubiquitin–pro-
teasome pathway is suppressed at the transcriptional level in
the aged brain (Lee et al., 2000). Proteasome activity was
also found to decrease in the aged rat brain (Keller et al.,
2000). We observed similar decreased activity of both chy-
motrypsin-like proteasomes and postglutamyl peptidase in
the striatum, which is particularly vulnerable in HD (Von-
sattel et al., 1985). Thus, the age-dependent decrease in pro-
teasome activity may reduce the clearance of degraded htt
and contribute to the progressive accumulation of NH2-ter-
minal mutant htt fragments. Consistent with this idea, pro-
teasome inhibition results in the accumulation of HD exon
1 protein in transfected cells (Waelter et al., 2001) and other
NH2-terminal htt fragments generated in NG108 cells
(Lunkes et al., 2002). However, this paper shows that multi-
ple mutant htt NH2-terminal fragments were generated in
HEK293 cells after inhibiting the proteasomes promotes.
More importantly, the generation of multiple mutant NH2-
terminal htt fragments naturally occurs in mouse brain and
is also increased by proteasome inhibition.
Because proteasome activity also decreases in various tis-
sues in aged animals, its age-dependent decrease is unlikely
to critically contribute to the specific neuropathology in
HD. The selective neuropathology of HD may be depen-
dent on the sensitivity of neurons to toxic htt fragments,
whereas the age-dependent decrease in neuronal proteasome
activity is more likely to promote the disease process medi-
ated by misfolded proteins.
Recent studies show that polyQ inclusions sequester pro-
teasomes and reduce proteasome activity in cultured cells
(Bence et al., 2001). It is possible that aggregated htt may af-
fect proteasome function when it forms large inclusions or
when cells are under stress. The presence of fewer htt inclu-
sions in our cell lines might not allow us to observe the effect
of htt inclusions on proteasome activity. Similarly, we did
not find that brain proteasome activity is specifically altered
in HD repeat knockin mouse brain as compared with age-
matched wild-type mice. Rather, we observed that neuronal
proteasome activity is decreased over time and that this age-
dependent decrease is associated with the accumulation of
NH2-terminal htt fragments and their aggregation.
Our study also suggests that proteolysis of mutant htt does
not bear analogy to that of the amyloid protein, whose cleav-
age by a few defined secretases produces distinct toxic
fragments in Alzheimer’s disease (Esler and Wolfe, 2001).
PolyQ proteins may be more accessible to a number of pro-
teases and further degradation by the ubiquitin–proteasome
systems. This paper suggests that improving and restoring a
cell’s ability to clear toxic protein fragments would be a more
effective route to reducing the toxicity of NH2-terminal htt
fragments. Martin-Aparicio et al. (2001) demonstrated that
proteasome inhibition can abolish the reversal of the expres-
sion and aggregation of mutant htt in HD mice, which also
suggested that decline in proteasome activity plays a role in
late onset pathology. Given the critical role of the protea-
some in removing toxic and misfolded proteins and the age-
dependent decrease in its activity, drugs and chemicals that
improve the function of the proteasome in aged neurons
may provide effective intervention to slow or prevent the
progression of HD and other age-dependent neurodegenera-
tive diseases in which toxic proteins are misfolded.
Materials and methods
HD mice and postmortem brains of HD patients
HdhCAG150 mice, which express a 150-CAG repeat in the endogenous
mouse HD gene, were generated previously and provided by P. Detloff
(University of Alabama at Birmingham, Birmingham, AL) (Lin et al., 2001).
These HD mice were maintained in the animal facility at Emory University.
Brain tissues from HdhCAG150 mice at various ages were used for analysis.
Frozen human brain tissues from pathologically normal individuals,
Alzheimer’s disease, and HD patients were provided by the Harvard Brain
Tissue Resource Center. The caudate brain region was obtained from five
HD patients aged from 39 to 75, and the postmortem interval was between
12 and 27 h. The pathological severity of these brains is grade 3 based on
published criteria (Vonsattel et al., 1985). Expanded CAG repeats (41–47 U)
in these HD brains were confirmed by PCR of brain genomic DNA using
an established method (Mende-Mueller et al., 2001).T
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Antibodies
EM48, a rabbit pAb against the NH2-terminal region (amino acids 1–256)
of human htt, was generated from our previous paper (Gutekunst et al.,
1999). Mouse mAb mEM48 was generated using the same antigen as for
the rabbit EM48 (Li et al., 2002). EM121 was a rabbit antibody generated
using GST-HD2 fusion proteins containing amino acids 342–456 of hu-
man htt (Covance, Inc). Mouse mAbs to  -tubulin (Sigma-Aldrich), htt
(2166 and 1C2; CHEMICON International, Inc.), and neuron-specific nu-
clear protein NeuN (CHEMICON International, Inc.) were also used.
cDNA constructs and transfection of cells
pEBVHis (Invitrogen) expression constructs containing full-length human
htt with 23 (23Q-F) or 120 (120Q-F) glutamines in the repeat were trans-
fected into HEK293 cells. We selected stable transfected htt cells with 500
ng/ml of the antibiotic hygromycin and obtained four independent lines of
120Q-F and six lines of 23Q-F. HEK293 cells were originally obtained
from American Type Culture Collection and were used to generate stably
transfected cells. The 120Q-F-1 and 23Q-F-5 cell lines were used for fur-
ther analysis. Htt cDNAs containing the first 508 aa with 23 (N508-23Q)
or 120 (N508-120Q) glutamines were obtained from our previous paper
(Gutekunst et al., 1999) and used for transfection of HEK293 cells.
Western blots, fractionation, and light microscopic examination
Homogenates of brain tissue and cultured cells were resuspended in PBS
with protease inhibitor cocktail (1  P8340; Sigma-Aldrich), 100  g/ml
PMSF, and 1% Triton X-100. Western blotting was performed using 4–12%
or 4–20% polyacrylamide Tris-Glycine gels (Invitrogen) and ECL kits (Am-
ersham Biosciences).
To isolate the nuclear fraction, brain tissue was homogenized in buffer
(0.25 M sucrose, 15 mM Tris-HCl, pH 7.9, 60 mM KCL, 15 mM NaCl, 5
mM EDTA, 1 mM EGTA, and 100  g/ml PMSF). The homogenate was
spun at 1,000 g for 15 min at 4 C. The cytosolic fraction was further iso-
lated by centrifuging at 20,000 g for 15 min. The nuclear pellet was
washed and resuspended in 1% SDS and spun down again at 20,000 g for
15 min. SDS resistant aggregates were isolated as described previously
(Hazeki et al., 2002). They were washed twice with 60 mM Tris-HCl, pH
7.6, and precipitated by centrifugation at 20,000 g for 15 min. To dissolve
htt aggregates, we treated the precipitated aggregates with 100% formic
acid at 37 C for 30 min. The sample was resuspended in 0.1% SDS and
dried under vacuum. The dried material was resuspended in 400  l H2O
and precipitated with methanol/chloroform (Wessel and Flugge, 1984).
The precipitated proteins were analyzed by Western blotting.
Immunostaining of brain sections and cultured cells was performed as
described previously (Li et al., 2000, 2002). Light microscopic graphs of
brain sections were taken at a magnification of 400 using a microscope
(model Axioskop 2; Carl Zeiss MicroImaging, Inc.) connected with a Spot-
RT digital camera (Diagnostic Instruments). Immunofluorescent images of
samples, which were stained with secondary antibodies conjugated with
either FITC or rhodamine (Jackson ImmunoResearch Laboratories), were
taken using an inverted fluorescent microscope (model Axiovert 135; Carl
Zeiss MicroImaging, Inc.) and video system (Dage-MTI Inc.) at a magnifi-
cation of 400. The captured images were stored and processed using
Adobe Photoshop software. To examine morphological changes of cul-
tured cells, htt-transfected cells were cultured for 3 d in the normal me-
dium, incubated with serum-free medium for 12 h, and treated with 10
mM 3-NP overnight. The cells were fixed, stained with mEM48 and
Hoechst, and remained in PBS for examination with fluorescent micros-
copy at room temperature. Cells showing abnormal nuclear morphology
or fragmentation were counted to obtain the percentage of dead cells. The
data were obtained from four independent 3-NP treatments by examining
271–689-transfected cells for each group.
Cell viability assays
Cell viability was determined by a modified MTS assay (Cell Titer 96;
Promega) with a microplate reader (SPECTRAmax Plus; Molecular De-
vices) as described previously (Li et al., 1999). For drug treatment experi-
ments, cultured cells were treated with 5 mM 3-NP or 200  M hydrogen
peroxide for 12 h and examined with the MTS assay.
In vitro degradation of htt
In vitro–translated htt was obtained from PRK-htt constructs encoding the
first 508 aa of htt using the TNT in vitro translation kit (Promega). Mouse
tissues were homogenized in five volumes of PBS. The low speed (1,000 g)
supernatant (100  g protein /30  l) was used for incubation (37 C for 1 h)
with 2  l of the in vitro–synthesized htt followed by termination with SDS
sample buffer. To inhibit the in vitro cleavage of htt, 50  M caspase inhib-
itor ZVAD (Enzyme Systems), protease inhibitor mix (consisting of pepsta-
tin A, leupeptin, and chymostatin at 10  M each, E64 and PMSF at 1  M
each in 1  P8340; Sigma-Aldrich), or 20  g/ml proteasome inhibitor
ALLN or 20  M lactacystin (Qbiogene) was preincubated with tissue ex-
tracts for 45 min at 37 C. In vitro–synthesized htt without protease inhibi-
tors showed multiple fragments and was used for further digestion by
mouse brain extracts. Degraded products of htt were analyzed by Western
blotting with 1C2 or mEM48. Densitometry was used to obtain relative ra-
tios of the intact form of N508 htt to tubulin.
Proteasome activity assay
A fluorogenic peptide substrate assay for proteasome activity was per-
formed as described previously (Figueiredo-Pereira et al., 1994; Canu et
al., 2000). Brain tissues and cultured cells were homogenized in lysis
buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 2 mM ATP, 20% glycerol,
and 4 mM DTT). The homogenate was centrifuged at 14,000 g at 4 C for
30 min. 20  g of cell lysate proteins or 40  g of nuclear proteins were in-
cubated with 0.4 ml of proteasome activity assay buffer (50 mM Tris-HCl,
pH 8.0, 1 mM EDTA, 1 mM ATP, and 40  M Suc-LLVY-MCA; Qbiogene).
The assay monitored the hydrolysis of the fluorogenic substrate, Suc-LLVY-
MCA, into 7-amino-4-methyl-coumarin. To examine postglutamyl pepti-
dase activity, we used 400  M N-CBZ-Leu-Leu-Leu-Glu– -naphthylamide
(Sigma-Aldrich). A linear correlation between the proteasome activity and
the reaction time was obtained at various times (15, 30, 45, 60, and 120
min). The reactions were stopped by adding 0.8 ml of cold water and incu-
bating on ice for 10 min. The fluorescent intensity of each reaction was
measured by fluorescence spectrophotometry (Fluostar Galaxy; BMG Lab-
technologies) at 390 nm excitatory and 460 nm emission wavelengths. The
background was obtained by incubating tissue samples with 1  M of the
proteasome inhibitor MG132 for 1 h at 37 C. The proteasome activity is
expressed as nanomol/minute/milligram protein (mean   SD).
Statistical analyses
A t test was used for simple comparison. To compare multiple groups to a
common control, the one way ANOVA was performed with subsequent
posthoc Scheffe’s test software, which is available at http://www.analyse-
it.com/scheffe-test_y.htm.
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